Monopar Therapeutics stock approaches $125.77 resistance as bullish momentum drives gains

Traders Union
All News
Stocks
Monopar Therapeutics jumps 6.91% today

Highlights

MNPR/USD maintains a bullish trend across all timeframes, trading well above key moving averages.
Momentum indicators are mixed, with strong buying pressure and several overbought signals increasing risk of reversal.
Expected trading range is $114.1019 to $125.77, with a 77% probability of further upside and key support at $112.3725.

Uptrend risks overextension as oscillators flag extreme buying

The MA-20 sits at $113.28, MA-50 at $110.68, and the long-term MA-200 at $71.12, all below the current price. The Ichimoku Kijun level at $112.37 is the nearest support. MACD signals ongoing buy momentum, while ADX remains neutral. RSI and CCI are in overbought territory, and both Stoch RSI and Bull/Bear Power also confirm buyer dominance. The Awesome Oscillator aligns with the prevailing bullish momentum, but several oscillators highlight that buying pressure is approaching extreme levels, raising the risk of an overextension.

Consolidation likely as volatility and breakout risk converge

In the short term, MNPR is likely to consolidate between $114.10 and $125.77, reflecting typical volatility at current levels. The probability of further upside stands at 77%, making a bullish scenario more likely. A breakout above $125.77 could signal resumed upside momentum, while a pullback below $112.37 would be required to trigger a bearish reversal.

Viktoras Karapetjanc, Traders Union expert, notes MNPR’s strong momentum as it surges above all major moving averages. He sees buyers firmly in control, with oscillators showing powerful but potentially overextended demand. While the absence of news removes a potential catalyst, technicals show a clear bullish setup with only overbought signals as caution. Karapetjanc believes a breakout above $125.77 could drive further gains in the short term. "Momentum favors the bulls, and as long as support near $112.37 holds, I expect further upside in MNPR."

Earlier, analysts noted that Monopar Therapeutics was demonstrating resilient bullish momentum amid signals of potential consolidation. The current surge reinforces this positive trend, but traders should closely watch for any signs of exhaustion near the upper end of the new trading band as overbought conditions raise the prospect of increased volatility ahead.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.